{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:47:35Z","timestamp":1791298055548,"version":"4.1.0"},"reference-count":22,"publisher":"University of Tokushima Faculty of Medicine","issue":"3.4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Invest."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2152\/jmi.64.205","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T22:55:19Z","timestamp":1506466519000},"page":"205-209","source":"Crossref","is-referenced-by-count":10,"title":["A phase I clinical trial for [<sup>131<\/sup>I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma: a study protocol"],"prefix":"10.2152","volume":"64","author":[{"given":"Anri","family":"Inaki","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Innovative Clinical Research Center, Kanazawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Murayama","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Kanazawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Data Center, Innovative Clinical Research Center, Kanazawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Kuribayashi","sequence":"additional","affiliation":[{"name":"Department of Monitoring and Auditing in Clinical Trials, Innovative Clinical Research Center, Kanazawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Jinguji","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kagoshima University Graduate School of Medical and Dental Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Shiga","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"925","reference":[{"key":"1","unstructured":"1. Lenders JW, Eisenhofer G, Mannelli M, Pacak K: Phaeochromocytoma. Lancet 366(9486): 665-75, 2005. doi: 10. 1016\/S0140-6736(05)67139-5. PubMed PMID: 16112304."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, et al: Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocrine-related cancer 21(3): 405-14, 2014. doi: 10. 1530\/ERC-13-0494. PubMed PMID: 24521857.","DOI":"10.1530\/ERC-13-0494"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Plouin PF, Chatellier G, Fofol I, Corvol P: Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 29(5): 1133-9, 1997. PubMed PMID: 9149678.","DOI":"10.1161\/01.HYP.29.5.1133"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. van Heerden JA, Roland CF, Carney JA, Sheps SG, Grant CS: Long-term evaluation following resection of apparently benign pheochromocytoma(s)\/paraganglioma(s). World journal of surgery 14(3): 325-9, 1990. PubMed PMID: 1973322.","DOI":"10.1007\/BF01658516"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF: Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. The Journal of clinical endocrinology and metabolism 90(4): 2110-6, 2005. doi: 10. 1210\/jc. 2004-1398. PubMed PMID: 15644401.","DOI":"10.1210\/jc.2004-1398"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, et al: Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Annals of internal medicine 109(4): 267-73, 1988. PubMed PMID: 3395037.","DOI":"10.7326\/0003-4819-109-4-267"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, et al: Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-related cancer 11(3): 423-36 , 2004. PubMed PMID: 15369446.","DOI":"10.1677\/erc.1.00829"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, et al: One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. The Journal of clinical endocrinology and metabolism 98(10): 4006-12, 2013. doi: 10. 1210\/jc. 2013-1907. PubMed PMID: 23884775.","DOI":"10.1210\/jc.2013-1907"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP: Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clinical endocrinology 81(5): 642-51, 2014. doi: 10. 1111\/cen. 12542. PubMed PMID: 25041164.","DOI":"10.1111\/cen.12542"},{"key":"10","unstructured":"10. Wieland DM, Swanson DP, Brown LE, Beierwaltes WH: Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J Nucl Med 20(2): 155-8, 1979. PubMed PMID: 430189."},{"key":"11","unstructured":"11. Shapiro B: A review of the status of radio-iodinated-MIBG therapy for neuroendocrine tumors. Int Med 2: 61-8, 1991"},{"key":"12","unstructured":"12. Castellani MR, Chiti A, Seregni E, Bombardieri E: Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. The quarterly journal of nuclear medicine: official publication of the Italian Association of Nuclear Medicine 44(1): 77-87, 2000. PubMed PMID: 10932604."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS, Jr., et al: Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134(6): 956-62, 2003. discussion 62-3. doi: 10. 1016\/S0039. PubMed PMID: 14668728.","DOI":"10.1016\/S0039-6060(03)00426-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP: (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clinical endocrinology 80(4): 487-501, 2014. doi: 10. 1111\/cen. 12341. PubMed PMID: 24118038.","DOI":"10.1111\/cen.12341"},{"key":"15","unstructured":"15. Kinuya S, Yoshinaga K, Higuchi T, Jinguji M, Kurihara H, Kawamoto H: Draft guidelines regarding appropriate use of I-MIBG radiotherapy for neuroendocrine tumors: Guideline Drafting Committee for Radiotherapy with I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine. Ann Nucl Med: 2015. doi: 10. 1007\/s12149-015-0960-z. PubMed PMID: 25773397."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G, Eanm: EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 35(5): 1039-47, 2008. doi: 10. 1007\/s00259-008-0715-3. PubMed PMID: 18274745.","DOI":"10.1007\/s00259-008-0715-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC: The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. Journal of endocrinological investigation 20(11): 648-58, 1997. PubMed PMID: 9492103.","DOI":"10.1007\/BF03348026"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al: Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clinical endocrinology 55(1): 47-60, 2001. PubMed PMID: 11453952.","DOI":"10.1046\/j.1365-2265.2001.01309.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gedik GK, Hoefnagel CA, Bais E, Olmos RA: 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 35(4): 725-33, 2008. doi: 10. 1007\/s00259-007-0652-6. PubMed PMID: 18071700.","DOI":"10.1007\/s00259-007-0652-6"},{"key":"20","unstructured":"20. Castellani MR, Seghezzi S, Chiesa C, Aliberti GL, Maccauro M, Seregni E, et al: (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine 54(1): 100-13, 2010. PubMed PMID: 20168292."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yoshinaga K, Oriuchi N, Wakabayashi H, Tomiyama Y, Jinguji M, Higuchi T, et al: Effects and safety of I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registry. Endocrine journal: 2014. PubMed PMID: 25214026.","DOI":"10.1507\/endocrj.EJ14-0211"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Wakabayashi H, Taki J, Inaki A, Nakamura A, Kayano D, Fukuoka M, et al: Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma. Ann Nucl Med 27(9): 839-46, 2013. doi: 10. 1007\/s12149-013-0755-z. PubMed PMID: 23864328.","DOI":"10.1007\/s12149-013-0755-z"}],"container-title":["The Journal of Medical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/64\/3.4\/64_205\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T13:52:38Z","timestamp":1659534758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/64\/3.4\/64_205\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":22,"journal-issue":{"issue":"3.4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2152\/jmi.64.205","relation":{},"ISSN":["1343-1420","1349-6867"],"issn-type":[{"value":"1343-1420","type":"print"},{"value":"1349-6867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}